Diagnostic and Prognostic Values of EUS-FNA Specimens and Circulating Exosomal Small RNA in Patients With Pancreatic Cancer
试验速览
- 阶段
- 不适用
- 入组人数
- 102
- 试验地点
- 1
- 主要终点
- senstivity
研究概览
简要总结
This study is for the verification of biomarkers for pancreatic cancer treatment using small RNA liquid biopsy, combined with EUS-FNA tissues.
详细描述
CA19-9 is the FDA approved biomarker for the diagnosis of pancreatic cancer. However, the specificity of CA19-9 to differentiate between pancreatic cancer, cholangiocarcinoma, or other pancreatic lesions is not satisfying enough.
Tumor cells secret abundant exosomes in the early stage. Circulating tumor cells are detected mainly in the advanced stage. Meanwhile, the role of non-coding RNA draws more and more attention in tumor area. Exosomes protect inside RNA from plasma RNase. Compared with long RNA, small RNA, including miRNA, snoRNA, tRNA, piRNA could exist more stably.
By means of next-generation sequencing, we look forward to finding new exosomal small RNA biomarkers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Diagnostic
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •pancreatic cancer patients
- •pancreatic lesions other than PAAD
- •chronic pancreatitis
- •cholangiocarcinoma
排除标准
- •diagnosed with other pathological types of cancer
- •treated with chemo/radio/surgery previously
结局指标
主要结局
senstivity
时间窗: up to 8 weeks
sensitivity of exo-sRNA
specificity
时间窗: up to 8 weeks
specificity of exo-sRNA to differentiate between PAAD and other benigh or malignant pancreatic occupying lesions
次要结局
- survival time(up to 18 months)
研究者
Bin Cheng
Professor
Huazhong University of Science and Technology